Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24707809 | 0.82 | CA12 (0.31) | LMNA | |
| SCHEMBL25132577 | 0.78 | MAOA (0.30) | — | |
| SCHEMBL12205473 | 0.78 | CHRNB2 (0.40) | ALDH1A1 | |
| SCHEMBL13434931 | 0.78 | LMNA (0.55) | LMNAMEN1KMT2AHCRTR2MMP1 | |
| SCHEMBL19275262 | 0.76 | CHRNB2 (0.30) | — | |
| SCHEMBL20326180 | 0.74 | LMNA (0.41) | LMNAMEN1KMT2AHCRTR2MMP1 | |
| SCHEMBL25724265 | 0.74 | PIK3CD (0.38) | LMNAALDH1A1 | |
| SCHEMBL21565937 | 0.73 | LMNA (0.50) | LMNAMEN1KMT2AHCRTR2MMP1 | |
| SCHEMBL25931952 | 0.72 | ACACB (0.32) | — | |
| SCHEMBL14577189 | 0.71 | CA12 (0.45) | LMNAMEN1KMT2AHCRTR2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9775831-B2 | Combinations comprising biphenyl derivatives for use in the treatment of HCV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775831-B2 | Combinations comprising biphenyl derivatives for use in the treatment of HCV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160166545-A1 | COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV | BRISTOL MYERS SQUIBB CO (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166545-A1 | COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV | HAVCR2, EIF2AK2, MAVS | LMNA 4523/4885MEN1 4864/4885KMT2A 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.